Lefter to the Editor

Neurodegenerative disorders, gut human microbiome and diet: future research for prevention and supportive therapies

Dear Editor,

Customized drugs, individual risk assessment on genetic basis and precision medicine were topics of great scientific interest in the last two decades¹. Genetic research has also been applied to neurodegenerative diseases, such as multiple sclerosis (MS): the study of Tamam et al² highlighted that men with MS and carriers of APOE ϵ^4 showed a severe form of the disease. The authors outlined the prognosis of MS adding valuable information on clinical choices through genetic study. Starting from the study of Tamam et al² and considering that only 1% of our genetic heritage is human, while the remainder is predominantly of bacterial origin³, we questioned if it will have to focus on the study of the microbiome for future researches in neurodegenerative diseases. Technological advances and application of sequencing in microbiome research allowed identification first clues about the role of microbes on neurological health, as demonstrated by the scientific evidences⁴. In MS, Pennisi et al⁵ showed an increase in oxidative stress markers, suggesting that use of molecules against oxidative stress should contribute to neurodegenerative prevention. A diet therapy, without junk or highly processed food, but rich in organic foods containing fibers and antioxidants, such as polyphenols, is able to increase the antioxidant capacity of the blood^{6,7}, ensure a balanced intestinal flora and a positive modulation of immune response8. Since in MS are present alterations of microbiota, such as reduction and alteration of bacteria species, that cause immune-modulatory disorders², it could useful associate anti-inflammatory, antioxidant diets and probiotic supplements with conventional therapy.

Conflict of interest

The authors declare no conflicts of interest.

References

- 1) Di Renzo L, Bianchi A, Saraceno R, Calabrese V, Cornelius C, Iacopino L, Chimenti S, De Lorenzo A. -174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers. Pharmacogenet Genomics 2012; 22: 134-142.
- 2) TAMAM Y, TASDEMIR N, YALMAN M, TAMAM B. Association of apolipoprotein E genotypes with prognosis in multiple sclerosis. Eur Rev Med Pharmacol Sci 2011; 15: 1122-1130.
- 3) Tremlett H, Bauer KC, Appel-Cresswell S, Finlay BB, Waubant E. The gut microbiome in human neurological disease: a review. Ann Neurol 2017; 81: 369-382.
- Mowry EM, Glenn JD. The dynamics of the gut microbiome in multiple sclerosis in relation to disease. Neurol Clin 2018; 36: 185-196.
- PENNISI G, CORNELIUS C, CAVALLARO MM, SALINARO AT, CAMBRIA MT, PENNISI M, BELLA R, MILONE P, VENTIMIGLIA B, MIGLIORE MR, DI RENZO L, DE LORENZO A, CALABRESE V. Redox regulation of cellular stress response in multiple sclerosis. Biochem Pharmacol 2011; 82: 1490-1499.

- 6) DI RENZO L, CARRARO A, VALENTE R, IACOPINO L, COLICA C, DE LORENZO A. Intake of red wine in different meals modulates oxidized LDL level, oxidative and inflammatory gene expression in healthy people: a randomized crossover trial. Oxid Med Cell Longev 2014; 2014: 681318.
- 7) DI RENZO L, DI PIERRO D, BIGIONI M, SODI V, GALVANO F, CIANCI R, LA FAUCI L, DE LORENZO A. Is antioxidant plasma status in humans a consequence of the antioxidant food content influence? Eur Rev Med Pharmacol Sci 2007; 11: 185-192.
- S) Soldati L, Di Renzo L, Jirillo E, Ascierto PA, Marincola FM, De Lorenzo A. The influence of diet on anti-cancer immune responsiveness. J Transl Med 2018; 20: 16: 75

L. Romano¹, P. Gualtieri², F. Nicoletti³, G. Merra⁴

¹Specialization School of Food Science, University of Rome Tor Vergata, Rome, Italy ²Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy ³School of Applied Medical-Surgical Sciences, University of Rome Tor Vergata, Rome, Italy ⁴Emergency Department, IRCSS "Agostino Gemelli" General Hospital Foundation, Catholic University of Sacred Heart, Rome, Italy